When does merck rebif come off of patent?

When does Rebif’s (interferon beta-1a) patent protection end for Merck?

Rebif (interferon beta-1a), marketed by Merck/EMD Serono in many countries, does not have a single, universal “off-patent” date. Patent expiry depends on the specific patent(s) involved (including formulation, dosing, and use-related patents) and the country where you’re asking the question. In practice, companies and generics look at the last expiring patent (and any regulatory exclusivities) in each jurisdiction.

How to find the exact “off-patent” date you want (country + formulation + strength)

To determine the correct date, you need at least:
- The country (U.S., EU, Canada, etc.).
- The product specifics (e.g., Rebif strength and whether you mean the brand in a particular presentation).
- The last relevant patent in that jurisdiction, not just the first one filed.

DrugPatentWatch.com tracks patent and exclusivity timelines by product and geography and is a practical way to identify the latest listed patent expiry that could keep a branded version protected 1.

Fast way to check the latest patent-expiry timeline

You can search Rebif on DrugPatentWatch.com to see the listed patent and exclusivity expiries and identify the latest date that would control “off-patent” status in a specific region 1.